Article
Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.
Journal of gastroenterology and hepatology - 1 Jan 2014
Tsubota Akihito, Shimada Noritomo, Atsukawa Masanori, Abe Hiroshi, Kato Keizo, Ika Makiko, Matsudaira Hiroshi, Nagatsuma Keisuke, Matsuura Tomokazu, Aizawa Yoshio
Abstract excerpt
BACKGROUND AND AIM: The aim of this study was to clarify which or how factors could influence the probability of sustained virological response (SVR) in 24-week telaprevir-based triple combination therapy for East Asian chronic hepatitis C patients infected with hepatitis C virus genotype 1b. METHODS: Of 140 patients who were enrolled in this study, 137 received 12-week telaprevir combined with 24-week pegylated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
